Table 1

List of outcomes reported across the included studies

OutcomesNumber of studies
Clinical 62
 Complete or partial response23
 Clinical remission10
 Symptoms resolution10
 Relapse7
 Time to development of attacks4
 Time to resolution of attacks4
 Clinical response3
 AIDAI3
 Reduction in attack frequency3
 Change in attack length2
 Clinical improvement1
Biochemical markers 40
 CRP34
 SAA26
 ESR17
 Biochemical remission/response2
 Haemoglobin2
 Platelet count2
 Mevalonic acid1
Patient reported outcomes 23
 PhGA17
 PtGA9
HRQoL
 SF-363
 CHAQ/HAQ3
 CHQ-PF503
 FACIT-F1
 DLQI1
 RAND-361
 Not reported1
Safety 35
Others 12
 Hearing-related9
 Neurological5
 Visual4
 Pregnancy-related1
 Musculoskeletal1
Switching between anti-IL-1 agents 13
 From anakinra to canakinumab11
 Canakinumab to anakinra3
  • AIDAI, Auto-inflammatory Disease Activity Index; CHAQ, Child Health Assessment Questionnaire; CHQ-PF50, Child Health Assessment Questionnaire—Parent Form; CRP, C reactive protein; DLQI, Dermatology Life Quality Investigation; ESR, erythrocyte sedimentation rate; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HRQoL, health-related quality of life; IL-1, interleukin 1; PhGA, Physician assessed Global assessment of disease; PtGA, patient/parent assessed Global assessment of disease; RAND-36, RAND-36 Health Survey; SAA, serum amyloid A; SF-36, 36-item Short-Form Health Survey.